IP Group has committed a total of $6.6m to a series A round for Enterprise Therapeutics, which had previously attracted capital from Touchstone Innovations.

Enterprise Therapeutics, a UK-based respiratory diseases-focused biopharmaceutical spinout from University of Sussex, closed a £29m ($41m) series B round yesterday that featured commercialisation firm IP Group.

The round was co-led by Novartis Venture Fund, the corporate venturing arm of pharmaceutical firm Novartis, and venture capital firm Versant Ventures. It also featured Epidarex Capital and Forbion.

IP Group has committed a total of $6.6m to the round, which will be supplied in tranches and is subject to Enterprise Therapeutics achieving certain…